Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

BACKGROUND: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and Enza have shown similar overall survival (OS) ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuzzo, Pier Vitale, Ravera, Francesco, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valença, Loana Bueno, Oliveira, Thiago Martins, Vauchier, Charles, Pereira Mestre, Ricardo, Modesti, Mikol, Patrikidou, Anna, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989439/
https://www.ncbi.nlm.nih.gov/pubmed/36895852
http://dx.doi.org/10.1177/17588359231156147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989439/
https://www.ncbi.nlm.nih.gov/pubmed/36895852
http://dx.doi.org/10.1177/17588359231156147

Ejemplares similares